Beyond its preferential niche: Brucella abortus RNA down-modulates the IFN-γ-induced MHC-I expression in epithelial and endothelial cells

Brucella abortus (Ba) is a pathogen that survives inside macrophages. Despite being its preferential niche, Ba infects other cells, as shown by the multiple signs and symptoms humans present. This pathogen can evade our immune system. Ba displays a mechanism of down-modulating MHC-I on monocytes/macrophages in the presence of IFN-γ (when Th1 response is triggered) without altering the total expression of MHC-I. The retained MHC-I proteins are located within the Golgi Apparatus (GA). The RNA of Ba is one of the PAMPs that trigger this phenomenon. However, we acknowledged whether this event could be triggered in other cells relevant during Ba infection. Here, we demonstrate that Ba RNA reduced the surface expression of MHC-I induced by IFN-γ in the human bronchial epithelium (Calu-6), the human alveolar epithelium (A-549) and the endothelial microvasculature (HMEC) cell lines. In Calu-6 and HMEC cells, Ba RNA induces the retention of MHC-I in the GA. This phenomenon was not observed in A-549 cells. We then evaluated the effect of Ba RNA on the secretion of IL-8, IL-6 and MCP-1, key cytokines in Ba infection. Contrary to our expectations, HMEC, Calu-6 and A-549 cells treated with Ba RNA had higher IL-8 and IL-6 levels compared to untreated cells. In addition, we showed that Ba RNA down-modulates the MHC-I surface expression induced by IFN-γ on human monocytes/macrophages via the pathway of the Epidermal Growth Factor Receptor (EGFR). So, cells were stimulated with an EGFR ligand-blocking antibody (Cetuximab) and Ba RNA. Neutralization of the EGFR to some extent reversed the down-modulation of MHC-I mediated by Ba RNA in HMEC and A-549 cells. In conclusion, this is the first study exploring a central immune evasion strategy, such as the downregulation of MHC-I surface expression, beyond monocytes and could shed light on how it persists effectively within the host, enduring unseen and escaping CD8+ T cell surveillance.


Introduction
Ba is one of the intracellular bacterial species responsible for brucellosis, a chronic infectious disease handling a significant global impact [1,2].This condition is multisystemic affecting different tissues and organs [1].Brucellosis has been classified by the World Health Organization as one of the seven "neglected endemic zoonotic diseases of particular interest" [3,4].In fact, there is no licensed vaccine for use in humans.Furthermore, current livestock vaccines using live attenuated strains are known to cause human illness and occasionally abortion in vaccinated livestock and are therefore not a suitable solution for eradicating the disease on a large scale [5,6].Therefore, the deep understanding of the mechanisms and strategies employed by Ba to persist in the host is -and will be-crucial to the design of effective vaccines and treatments to control the disease in humans and other animals.
The infection in humans triggers the innate and adaptive immunity towards a Th1 profile with the consequent activation of CD8 + T cells [7][8][9].Despite this response, this bacterium employs several immune evasion strategies to chronically persist in host cells [10].Previous results from our laboratory demonstrate that one of the mechanisms displayed by Ba is the decrease of MHC-I on monocytes/macrophages surface when Th1 response is being held, i.e., in the presence of IFN-γ [11,12].As a result, the infected cells have a decreased capacity for antigenic presentation to CD8 + T cells [11,12].Moreover, we elucidated that Ba RNA, a pathogen-associated molecular pattern (PAMP) associated with bacterial viability (vita-PAMP), is a component involved in the diminished MHC-I expression [13,14].In addition, human TLR8, an endosomal receptor capable of sensing single-stranded RNA and RNA degradation products, is the receptor involved in MHC-I decrease [13,14].Regarding the signaling pathway, we demonstrated that Ba RNA-mediated down-modulation of MHC-I expression is dependent on the EGFR pathway [13][14][15].The decrease of MHC-I surface expression in monocytes/macrophages is not due to transcriptional and/or translational inhibition, instead these proteins are retained within the Golgi Apparatus (GA) [11].
As mentioned above, we have made substantial advances in the understanding of a central strategy for the bacterium: the downregulation of MHC-I expression.However, these studies only focused on the preferential intracellular niche for Ba, the monocyte/macrophage.As it is already known, Ba can also infect and replicate in different cell types such as lung epithelial and endothelial cells, osteoblasts, synoviocytes, hepatocytes, astrocytes, and microglia, among others [16][17][18][19][20][21][22][23][24].Considering that Ba may be acquired by humans through the inhalation of contaminated aerosols, the lung epithelium plays an important role in brucellosis.This epithelium is the first barrier that Brucella must overcome when infecting the respiratory system.Ba can trigger an inflammatory response in said pulmonary epithelium and generate different clinical manifestations, including empyema, pleural effusion, granulomas and solitary nodules, interstitial pneumonia, hilar and paratracheal lymphadenopathy, and pneumothorax.This is why the study of lung epithelium must be considered in the diagnosis as well as the management of the disease [25,26].Ferrero et al. demonstrated that lung epithelium plays an active role in the immune response against brucellosis secreting inflammatory mediators such as IL-8 y MCP-1, which contribute to the host immune response [16,17].
On the other hand, within the 5% mortality rate of human brucellosis, complications from endocarditis account for the largest share.Moreover, Brucella has been frequently isolated from affected aortic and/or mitral valves [2,27,28].This is why studying the role of the endothelial cells during Ba infection is key to understand the pathogenesis and the progression to a chronic condition.Ferrero et al. [18] has showed that Brucella spp.infect and survive in endothelial cells and can induce a proinflammatory response which may be involved in the vascular manifestations of patients with brucellosis.
Despite the crucial relevance of lung epithelial and endothelial cells in the context of brucellosis pathogenesis, up to now, there has not been studies of Ba immune evasion strategies on those cells.This research aims to investigate the long-term persistence of the disease in various organs of the infected host.It is the first study of its kind.
Here, we study for the first time whether Ba triggers strategies of immune evasion in other cell types and the effect of a drug already used in other diseases which could revert MHC-I down-modulation.More specifically, we assessed the effect of the RNA of Ba on the expression of MHC-I, as well as the preliminary mechanism and pathway involved in lung epithelial and endothelial cells.As model target cells we used A-549 (a human alveolar epithelium cell line), Calu-6 (a human bronchial epithelium cell line), and HMEC (an endothelial microvasculature cell line).We first determined whether Ba RNA was able to decrease MHC-I surface expression in all cell lines evaluated.We also investigated whether this phenomenon is caused by the retention of MHC-I in the GA, as it happens for human macrophages.Finally, we explored the capacity of Cetuximab, an inhibitor of the EGFR pathway, to revert the decrease of MHC-I surface expression.We present the results of this first study.

Bacteria strains
Brucella abortus S2308 was cultured in triptein soy agar medium.The number of bacteria on stationary-phase cultures was determined by comparing the optical density (OD) at 600 nm with a standard curve.All live Brucella manipulations were performed in Biosafety Level

Cell cultures
For all the experiments, THP-1, Calu-6, A-549 and HMEC cell lines were used.All experiments were performed at 37˚C in a 5% CO 2 atmosphere and a standard medium consisting in RPMI 1640 for THP-1 cells and HMEC or DMEM (Gibco) for A-549 and Calu-6 cells, supplemented with 25 mM Hepes, 2 mM L-glutamine, 10% heat-inactivated FBS (Thermo Fisher Scientific), 100 U penicillin/ml, and 100 μg streptomycin/ml.THP-1, Calu-6, A-549 and HMEC cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured, as previously described [29][30][31].THP-1 cells were treated with 1 ng/ml PMA (Sigma-Aldrich) for 24 h to promote adherence.Then they were washed, and complete medium was added for 72 h.For all the experiments carried out, the cell confluence was 80%.This study was approved by Academia Nacional de Medicina's Ethics Committee (number: 36/23/ CEIANM).

RNA preparation
5 x 10 9 CFU of Ba were resuspended in 1 ml of TRIzol (Invitrogen) and RNA was purified using Quick-RNA DirectZol columns (Zymo Research) according to the manufacturer's instructions.The quantification and purity of the RNA was determined using a DeNovix DS-11 spectrophotometer (DeNovix Inc.).In all cases, the absorbance ratio 260/280 was higher than 2.0, and the ratio 260/230 was higher than 1.8.

Viability assay
For viability assays, THP-1, Calu-6, A-549 and HMEC were treated with Ba RNA in the presence of IFN-γ for 48 h.Cells were washed with PBS buffer and resuspended in diluted 100 μl Zombie Violet™ solution to check the viability of the treated cells.Heat-killed cells were included as a positive control of the technique.Then, cells were incubated at room temperature, in the dark, for 15-30 minutes.The cells were then washed and surface antibody staining procedure was performed.After labelling, cells were analyzed with FACSCalibur (BD Biosciences) or Partec CyFlow (LabSystems) flow cytometers.Data was analyzed with FlowJo V10 software (FlowJo, LLC).
In vitro stimulation 2.5 x 10 5 THP-1 cells were treated with PMA (1 ng/ml) for 24 h to promote adherence.Then cells were washed, and complete medium was added for 72 h.Calu-6, A-549 and HMEC were incubated in 48-well plates (6 x 10 4 cells/well) for 24 h to promote adherence.Then, cells were stimulated with Ba RNA in the presence of IFN-γ for 48 h at 37˚C in a 5% CO 2 atmosphere.In all cases, the surface expression of MHC-I or the intracellular expression of TLR8 was evaluated by flow cytometry, as described in the following paragraph.

Flow cytometry
THP-1, Calu-6, A-549 and HMEC cells were stained with an anti-human MHC-I conjugated to FITC (W6/32) antibody or the corresponding isotype control antibody.All cell lines were permeabilized with Triton (0.1%) before being stained with an anti-human TLR8 conjugated to PE (clone 44C143; Invitrogen) antibody or the corresponding isotype control antibody.After labelling, cells were analyzed on a FACSCalibur flow cytometer (BD Biosciences) or Partec CyFlow (LabSystems) and data were processed with the FlowJo V10 applications (FlowJo, LLC).Data was normalized to untreated cells, i.e., in each set of experiments, the MFI of treatments (from the % of positive cells for the marker) was divided by MFI of media condition (from the % of positive cells for each marker).

Confocal microscopy
2.5 x 10 5 THP-1 cells were treated with 1 ng/ml PMA for 24 h to promote adherence in chamber-slides.Then they were washed, and complete medium was added for 72 h.6 x 10 4 cells/ well Calu-6, HMEC and A549 cells were incubated in chamber-slides for 24 h to promote adherence.Then, cells were stimulated with Ba RNA in the presence of IFN-γ for 48 h, fixed with 2% paraformaldehyde, permeabilized with 0.1% saponin and incubated with anti-HLA-ABC class I mAb W6/32 (BioLegend), and an Alexa 546-labelled secondary Ab (Invitrogen).Golgi apparatus was detected using a mAb specific for GM130 (BD Biosciences) following Alexa 488-labelled secondary Ab (Invitrogen).For nuclear staining, TOPRO-3 (Thermo Fisher Scientific) was used.Slides were mounted with PolyMount (Polysciences) and analyzed using FV-1000 confocal microscope with an oil-immersion Plan Apochromatic 60X NA1.42 objective (Olympus).

Determination of cytokine concentration
The concentration of different cytokines and chemokines (IL-8, IL-6 and MCP-1) was quantified in supernatants (SNs) from all cell lines stimulated with Ba RNA in the presence of IFN-γ for 48 h by ELISA sandwich, according to the manufacturer's instructions.The following detection kits were used: IL-6 (e-Bioscience), MCP-1 (BioLegend) and IL-8 (BioLegend).

Reagents
Antibody targeting EGFR (Cetuximab) was purchased from Merck Serono.The final concentration used was 50 μg/ml in all experiments.

Statistical analysis
Results were analyzed with one-way ANOVA followed by post hoc Tukey test or two-way ANOVA followed by post hoc Bonferroni test with GraphPad Prism software, 8.4.3 version.

Ba RNA diminishes MHC-I expression on different cell lines
To evaluate whether MHC-I down-modulation mediated by Ba RNA were mimicked in other cells able to be infected by Ba, cells from the human bronchial epithelium cell line (Calu-6), cells from the human alveolar epithelium cell line (A-549) and cells from the endothelial microvasculature cell line (HMEC) were stimulated with Ba RNA at different doses in the presence of IFN-γ for 48 h.Afterwards, MHC-I surface expression was determined by flow cytometry.As an experimental control, THP-1 cells were used.As shown, Ba RNA diminished MHC-I surface expression in all four cell lines (Fig 1A -1D).Cell viability was assessed using a  that Ba RNA down-modulates the IFN-γ-induced surface expression of MHC-I molecules on epithelial and endothelial cells.However, this is not an exclusive phenomenon of B. abortus RNA as it could be extended to other prokaryotic RNAs.

Ba RNA increases IL-8 and IL-6 secretion from different cell lines
Patients with chronic brucellosis show augmented levels of IFN-γ and other Th1 cytokines during active disease [32].With respect to endothelial and epithelium cells, Ferrero et al. demonstrated that the infection of HMEC cells with Ba led to an increased production of IL-8, MCP-1, and IL-6 [18].Also, IL-8 is augmented in Ba-infected Calu-6 cell supernatants but not in A549's [17].Therefore, to determine the effect of Ba RNA on the secretion of pro-inflammatory cytokines, Calu-6, A-549 and HMEC cells were stimulated with three doses of Ba RNA (1, 5 and 10 μg/ml) in the presence of IFN-γ.After 48 h, supernatants were collected, and IL-8, IL-6 and MCP-1 secretion was quantified by sandwich ELISA.No significant change in MCP-1 secretion was observed in cells treated with Ba RNA (Fig 3C).Contrary to our expectations, the treatment of Calu-6, A-549 and HMEC cells with Ba RNA resulted in higher levels of IL-8 and IL-6 compared to untreated cells (Fig 3A and 3B).These results indicated that although Ba RNA affects the expression of MHC-I in the different cell lines evaluated, it increases the production of some pro-inflammatory cytokines.

Ba RNA induces MHC-I retention in GA in Calu-6 and HMEC cell lines
Ba exhibits an immune evasion tool of down-modulating MHC-I on monocytes/macrophages in the presence of IFN-γ (when Th1 response is triggered).The overall expression of MHC-I is unchanged, but the proteins remain within the GA [11].We have shown that Ba RNA reduces the surface expression of MHC-I induced by IFN-γ in other cells which are susceptible to infection with Ba (Fig 1).However, it is unclear whether this phenomenon is caused by Ba RNA-mediated MHC-I retention within the GA, as is the case in human macrophages, which is its preferred niche.To assess this, Calu-6, A-549 and HMEC cells were stimulated with 10 μg/mL Ba RNA in the presence of IFN-γ.At 48 h, the expression of MHC-I and the marker GM130 of GA were detected using confocal microscopy.We identified three populations: Afterwards, we evaluated whether this phenomenon observed in the group of cells with "(DIM + NULL) MHC-I expression" corresponded to a retention of MHC-I in the GA.In both Calu-6 and HMEC cells, Ba RNA induced colocalization of MHC-I and GM130 (Fig 5).However, in A-549 cells there was no evidence of colocalization (Fig 5).Taken together, these results demonstrate that the Ba RNA-mediated MHC-I retention in GA previously observed in human macrophages can also be reproduced in other cell lines, particularly Calu-6 and HMEC.

Ba RNA-mediated MHC-I down-modulation involves the EGFR pathway in A-549 and HMEC cells
We previously demonstrated that Ba RNA reduces the MHC-I surface expression induced by IFN-γ on human monocytes/macrophages through a TLR8-dependent mechanism and the EGFR signaling pathway [13].To expand these results, Calu-6, A-549 and HMEC cells were stimulated with Ba RNA (10 μg/ml) in the presence of IFN-γ.After 48 h, the expression of TLR-8 in all cell lines was corroborated by flow cytometry (S3 Fig) .Subsequently, cells were treated with Ba RNA (10 μg/ml) in the presence of 50 μg/ml of Cetuximab (a ligand-blocking antibody of the EGFR).Neutralization of the EGFR partially reversed the down-modulation of MHC-I surface expression mediated by Ba RNA in A-549 and HMEC cells (Fig 6C and 6D).These results demonstrate that the EGFR pathway is involved in the down-modulation of MHC-I mediated by Ba RNA in A-549 and HMEC cells.

Discussion
Brucellosis remains being a neglected and complicated disease due to multiple reasons: it is sub-diagnosed, it could progress to a chronic disease, it occurs in multiple domestic and wild animals and as consequence, it causes socio-economic losses specially in low and middleincome countries where agricultural activities are fundamental [33].The disease has been classified as "one of the seven neglected endemic zoonotic diseases of particular interest" by the WHO [3,4].Consequently, studies focused on the pathogens responsible for this disease need to be expanded.Our laboratory has been mainly working in immune evasion strategies of Ba on monocytes/macrophages.Here, we present the very first study describing how Ba down- modulates MHC-I in cells -different from monocytes/macrophages-able to be infected with the pathogen.
Humans can get infected with Ba mainly through the consumption of raw dairy products, inhalation of contaminated aerosols, e.g.slaughterhouses and contact of injured skin with contaminated materials [1].In line with this, respiratory and endothelial cells are crucial in the development of the infection.Ferrero et al. have already described that Ba can infect and replicate in HMEC and in human line epithelial cells [16][17][18].However, it is in monocytes/macrophages where Ba finds its niche to persist chronically inside the host.
From the multiple resources that Ba employs to evade human immune response, MHC-I down-modulation is one of the most studied [11,13,15].In this study, we show that Ba RNAmediated MHC-I down-modulation previously described for monocytes/macrophages also occurs in human respiratory epithelial (CALU-6 and A549) and in endothelial cells (HMEC).
Reduction of MHC-I as an immune evasion strategy is a well described mechanism in virus infections [34][35][36][37].Recently, Koutsakos et al. (2019) described for the first time that Influenza A and B viruses down-modulates MHC-I expression in infected cells (with A549 being one of the studied) by different mechanisms [38].In bacterial infections, MHC-I down-regulation is not as common as for viruses.For instance, one pathogenic strain of S. typhimurium specifically downregulated MHC-II, but not MHC-I expression on porcine alveolar macrophages [39].On the other hand, Coxiella burnetii-infected DCs show impaired DC maturation and MHC-I expression [40].In our laboratory, we demonstrated that Ba downregulates MHC-II and MHC-I, and in both cases, Ba RNA is one of the PAMP that triggers this phenomenon [13,41].
The profile of the evaluated secreted cytokines merits discussion.Ba RNA stimulates the IFN-γ-induced secretion of the pro-inflammatory cytokines IL-8 and IL-6 in the studied cells.Regarding the latter, we and others have shown that Ba infection as well as Ba RNA stimulates the secretion of IL-6 in the presence or absence of IFN-γ [19,29,41,42].Indeed, IL-6 is the mediator of IFN-γ-induced MHC-II down-modulation in monocytes by lipoproteins [42] and by Ba RNA [41].Thus, it may not be surprising its role in this disease as a pro-inflammatory molecule, not only in phagocytes but in endothelial and epithelial cells equally.In this regard, Mitroulis et al. (2022) demonstrated that in a cohort of brucellosis patients, the levels of IFN-γ, IL-1β and IL-6 diminished significantly after treatment, while there was no difference in other measured cytokines such as MCP-1 [32].
About the retention of MHC-I molecules in the GA some highlights must be commented.In previous studies from our laboratory [11,13], we showed that Ba and Ba RNA diminished the IFN-γ-induced MHC-I expression in human monocytes by retaining these molecules in the GA.This is not due to a diminished MHC-I expression.Moreover, since we used W6/32 as the anti-HLA-ABC class I mAb, we know that detected MHC-I are properly assembled.Evidence of this phenomenon is very limited in the literature, for what this is in intriguing aspect of the mechanisms that this pathogen employs.Ba is not the unique pathogen capable of retaining MHC-I molecules in GA.The bovine papillomavirus affects MHC-I localization by retaining these molecules within GA in embryonic bovine cells [34].Varicella-zoster virus impaired the traffic of MHC-I from GA to the cell membrane [43].
Regarding the receptor, TLR8 has been recently characterized as being involved in infectious diseases.For instance, the detection of Streptococcus pyogenes RNA by this receptor is critical for triggering monocyte activation in response to the infection [44].Also, Cervantes et al. demonstrated that the transcription of IFN-β in response to Borrelia burgdorferi, is induced from within the phagosome vacuole through the TLR8-MyD88 pathway [45,46].We showed that human TLR8/murine TLR7 senses RNA from Ba promoting MHC-I down-modulation in monocytes and human/murine macrophages [13].In this manuscript, although we are not demonstrating a direct sensing of Ba RNA via TLR8 in the studied cell lines, we show its presence by flow cytometry.
We have previously shown that Cetuximab, a drug that blocks the EGFR, partially reverted MHC-I down-modulation by Ba and its RNA in monocytes/macrophages [13,15].In the present study, we wondered whether this drug was able to cause the same effect in other cell lines.Interestingly, we found that Cetuximab perform the same partial reversion in A549 and HMEC cell lines.For Calu-6 is particularly remarkable the fact that cells showed retention of MHC-I molecules within the GA, but Cetuximab did not even partially revert the phenomenon.These results led us postulate that, like in monocytes/macrophages, there would be a connection between TLR8 and EGFR, at least in A549 and HMEC.To our knowledge, this is the first report describing a link between these pathways in these alternative niches of infection.
Some limitations of this study should be considered.Brucellosis patients in Argentina are sub diagnosed; a reason why obtaining a blood sample is a difficult task.Murine models are useful to study this disease; however, we have not been able to carry out trials because the unique animal BSL-3 laboratory located in Buenos Aires, Argentina, is not available due to renovations after the COVID-19 pandemic.For future research work, we would like to find a representative number of samples from patients with brucellosis to perform at least cytokine measurements and detection of MHC molecules in PBMCs, which would help us deepen our understanding of the pathology.An in vivo model with Ba-infected mice is also desired to obtain different types of cells such as lung epithelial and endothelial cells, osteoblasts, synoviocytes, hepatocytes, astrocytes and microglia, among others, capable of being infected by Ba to evaluate their immune profile and functionality.
Overall, our results demonstrate that Ba and particularly its RNA down-modulates MHC-I on its preferential niche and in other potential focuses of infection such as endothelium and respiratory epithelium.This could propose new understanding in how the pathogen may persist indefinitely pleiotropically in the host evading T CD8 + surveillance.Also, we show that Cetuximab could contribute to revert MHC-I down-modulation in other relevant cells in brucellosis.These results expand our findings in macrophages and support the fact that Cetuximab is a promising drug to be, at least considered, for models of chronic brucellosis.

Fig 2 .
Fig 2. The MHC-I decrease mediated by Ba RNA is not due to a loss of cell viability.(A) THP-1, (B) Calu-6, (C) A-549 and (D) HMEC were attached on a 48-well plate for 24 h.Then, the cells were stimulated with three doses of Ba RNA (1, 5 and 10 μg/ml) in the presence of IFN-γ.After 48 h, cells viability was checked by staining the cells with Zombie Violet™ solution.A set of heat-killed cells was used as a positive control.****P<0.0001vs untreated cells.https://doi.org/10.1371/journal.pone.0306429.g002 cells with bright expression of MHC-I on the cell surface (named MHC-I BRIGHT), cells with dim expression of MHC-I on the cell surface (named MHC-I DIM), and cells with no MHC-I expression on the cellular surface (named MHC-I NULL) (Fig 4A).Cells were split in two groups: MHC-I BRIGHT cells and MHC-I DIM + NULL cells.The percentage of MHC-I DIM + NULL cells was augmented in cells treated with Ba RNA + IFN-γ compared to those treated only with IFN-γ in all cell lines (Fig 4B).These results corroborate the decrease in MHC-I expression observed in flow cytometry experiments (Fig 1).

Fig 4 .
Fig 4. Ba RNA increases the percentage of cells with (DIM + NULL) MHC-I expression.(A) Confocal microscopy images of THP-1, Calu-6, A-549 or HMEC cells treated with Ba RNA (10 μg/ml) in the presence of IFN-γ for 48 h.MHC-I expression was detected with an anti-human MHC-I primary Ab (W6/32) followed by Alexa 546-labeled secondary Ab (red).GA was determined using a mAb specific for GM130 and Alexa 488-labeled secondary Ab (green).Nucleus was detected using TOPRO-3 (blue).Orange arrows show representative cells of the different MHC-I expression (MHC-I DIM, MHC-I BRIGHT and MHC-I NULL cells).Cells treated with IFN-γ were used as a positive control.(B) Bars represent the percentage of cells with (DIM + NULL) MHC-I expression.-, untreated cells.*P<0.05;**P<0.01vs IFN-γ-treated cells.The number of cells counted per experimental group was 200.https://doi.org/10.1371/journal.pone.0306429.g004

Fig 5 .
Fig 5. Ba RNA reproduces the MHC-I retention in GA observed in human monocytes in Calu-6 and HMEC.(A) Confocal microscopy images of THP-1, Calu-6, A-549 or HMEC cells treated with Ba RNA (10 μg/ml) in the presence of IFN-γ for 48 h.MHC-I expression was detected with an anti-human MHC-I primary Ab (W6/32) followed by Alexa 546-labeled secondary Ab (red).GA was determined using a mAb specific for GM130 and Alexa 488-labeled secondary Ab (green).Nucleus was detected using TOPRO-3 (blue).The colocalization (yellow staining) is pointed with white arrows.Cells treated with IFN-γ were used as a positive control.(B) Bars indicate the percentage of cells with "(DIM + NULL) MHC-I expression" with their MHC-I colocalizing with GA.The number of cells counted per experimental group was 200.https://doi.org/10.1371/journal.pone.0306429.g005